The IPO Buzz: ARCH Venture’s Boundless Bio Files Plans for $100 Million IPO
ARCH Venture Partners is the big name behind Boundless Bio Inc. (BOLD Proposed), a Phase 1 cancer biotech that filed plans for a $100 million IPO on Wednesday (March 6, 2024) after the closing bell. The S-1 filing did not disclose terms for the IPO. This is a NASDAQ listing. Boundless Bio was founded in 2018 […]
March 7, 2024 Read More